Adverse Effect in Patients with Psoriasis Treated with Interleukin 17A Inhibitor- Secukinumab Cover

.blurhash-client-img { display: none !important; }

Adverse Effect in Patients with Psoriasis Treated with Interleukin 17A Inhibitor- Secukinumab

EABR. Experimental and Applied Biomedical Research

By: Ardea Milidrag, Medo Gutić, Ivana Rodić, Ana Pjevač, Tatjana Mladenović, Vesna Miličić and Ana Ravić-Nikolić

Open Access

|May 2022

Authors

Ardea Milidrag

ardeamilidrag1@gmail.com

University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia

Medo Gutić

University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia

Ivana Rodić

Ministry of Health of the Republic of Serbia, Inspection Sector

Ana Pjevač

Syenos Health, Medical and Scientific management

Tatjana Mladenović

Community Health centre Novi Beograd

Vesna Miličić

University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia

Ana Ravić-Nikolić

University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia

DOI: https://doi.org/10.2478/sjecr-2022-0013 | Journal eISSN: 2956-2090 | Journal ISSN: 2956-0454

Journal RSS Feed

Language: English

Submitted on: Aug 24, 2021

|

Accepted on: Mar 26, 2022

|

Published on: May 27, 2022

Published by: University of Kragujevac, Faculty of Medical Sciences

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

biological agents,

adverse events,

Related subjects:

Clinical medicine,

Clinical medicine, other

© 2022 Ardea Milidrag, Medo Gutić, Ivana Rodić, Ana Pjevač, Tatjana Mladenović, Vesna Miličić, Ana Ravić-Nikolić, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.